Insider Selling: Humacyte (NASDAQ:HUMA) CFO Sells 45,887 Shares of Stock

Humacyte, Inc. (NASDAQ:HUMA) CFO Dale Sander sold 45,887 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the sale, the chief financial officer owned 267,213 shares in the company, valued at approximately $240,491.70. This trade represents a 14.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Humacyte Stock Up 11.1%

Shares of Humacyte stock traded up $0.09 during trading on Wednesday, reaching $0.92. The stock had a trading volume of 4,271,551 shares, compared to its average volume of 6,504,970. The company has a market capitalization of $203.64 million, a price-to-earnings ratio of -1.61 and a beta of 2.31. The stock has a fifty day moving average price of $0.84 and a two-hundred day moving average price of $1.05. Humacyte, Inc. has a 52 week low of $0.55 and a 52 week high of $2.93. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.46 million. Sell-side analysts predict that Humacyte, Inc. will post -0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Humacyte

Institutional investors have recently bought and sold shares of the business. R Squared Ltd acquired a new position in Humacyte during the fourth quarter worth approximately $25,000. Atom Investors LP acquired a new position in Humacyte during the fourth quarter worth approximately $25,000. Truist Financial Corp acquired a new position in shares of Humacyte in the third quarter valued at approximately $28,000. Prudential Financial Inc. acquired a new position in shares of Humacyte in the second quarter valued at approximately $28,000. Finally, Financial Advisors Network Inc. acquired a new position in shares of Humacyte in the second quarter valued at approximately $28,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Trending Headlines about Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: Humacyte said its Symvess vascular graft is now under contract with the U.S. Department of Veterans Affairs Strategic Acquisition Center, which should make the product easier to access across 170 VA hospitals and may support broader adoption. Article Title
• Positive Sentiment: TD Cowen reportedly raised its price target on HUMA to $1.50 from $1.00, which can reinforce investor optimism around the stock’s potential. Article Title
• Neutral Sentiment: HC Wainwright updated its earnings estimates across several future periods, but the note still points to continued losses and only modest expected improvement over time.
• Negative Sentiment: The analyst revisions included lower EPS expectations for FY2026, FY2027 and FY2028, underscoring that Humacyte is still expected to remain unprofitable for the foreseeable future.

Wall Street Analyst Weigh In

HUMA has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a report on Friday, April 10th. Wall Street Zen raised Humacyte from a “strong sell” rating to a “sell” rating in a research report on Saturday. BTIG Research lowered their price target on Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Benchmark lowered their price target on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, January 21st. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Humacyte presently has a consensus rating of “Moderate Buy” and an average target price of $7.57.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.